

Madeleine Duvic

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6688498/publications.pdf>

Version: 2024-02-01

358
papers

24,889
citations

8208

78
h-index

9865

146
g-index

363
all docs

363
docs citations

363
times ranked

15423
citing authors

#	ARTICLE	IF	CITATIONS
1	Monitoring malignant Tâ€cell clones by direct TCR expression assay in patients with leukemic cutaneous Tâ€cell lymphoma during extracorporeal photopheresis. <i>Photodermatology Photoimmunology and Photomedicine</i> , 2022, 38, 158-168.	0.7	2
2	Granuloma Annulare: An Updated Review of Epidemiology, Pathogenesis, and Treatment Options. <i>American Journal of Clinical Dermatology</i> , 2022, 23, 37-50.	3.3	41
3	New Practical Aspects of Sweet Syndrome. <i>American Journal of Clinical Dermatology</i> , 2022, 23, 301-318.	3.3	36
4	Strategies to Optimize Adherence in Patients with Mycosis Fungoides. <i>Cells</i> , 2022, 11, 113.	1.8	1
5	Determination of immunophenotypic aberrancies provides better assessment of peripheral blood involvement by mycosis fungoides/SÅzary syndrome than quantification of <scp>CD26</scp>â’ or <scp>CD7</scp>â” <scp>CD4</scp>+ Tâ€cells. <i>Cytometry Part B - Clinical Cytometry</i> , 2021, 100, 183-191.	0.7	15
6	Quality of Life Effect of the Anti-CCR4 Monoclonal Antibody Mogamulizumab Versus Vorinostat in Patients With Cutaneous T-cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 97-105.	0.2	18
7	Is immunohistochemical expression of GATA3 helpful in the differential diagnosis of transformed mycosis fungoides and primary cutaneous CD30-positive T cell lymphoproliferative disorders?. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 479, 377-383.	1.4	5
8	Vulvar Primary Cutaneous CD8+ Aggressive Epidermotropic Cytotoxic T-Cell Lymphoma. <i>International Journal of Gynecological Pathology</i> , 2021, 40, 229-233.	0.9	1
9	Teledermatology During COVID-19: An Updated Review. <i>American Journal of Clinical Dermatology</i> , 2021, 22, 467-475.	3.3	37
10	Response to brentuximab vedotin versus physicianâ€™s choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis. <i>European Journal of Cancer</i> , 2021, 148, 411-421.	1.3	27
11	Postâ€transplantation donorâ€derived Sezary syndrome in a patient with <scp>A91V <i>PRF1</i></scp> variant hemophagocytic lymphohistiocytosis. <i>American Journal of Hematology</i> , 2021, 96, E350-E353.	2.0	2
12	Randomized phase 3 ALCANZA study of brentuximab vedotin vs physicianâ€™s choice in cutaneous T-cell lymphoma: final data. <i>Blood Advances</i> , 2021, 5, 5098-5106.	2.5	46
13	Cutaneous T-Cell Lymphoma and Cutaneous B-Cell Lymphoma. , 2020, , 1948-1964.e5.		0
14	Methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) is an important pathogen in erythrodermic cutaneous T-cell lymphoma (CTCL) patients. <i>Archives of Dermatological Research</i> , 2020, 312, 283-288.	1.1	18
15	Lymphomatoid Papulosis With a Unique T Follicular Helperâ€™Like Phenotype. <i>American Journal of Dermatopathology</i> , 2020, 42, 776-779.	0.3	2
16	Renal Cell Carcinoma Associated with Mycosis Fungoides: A Paraneoplastic Syndrome. <i>Case Reports in Nephrology</i> , 2020, 2020, 1-3.	0.2	2
17	Unmasking a T cell lymphoma: Folliculotropic mycosis fungoides with a gamma-delta phenotype. <i>JAAD Case Reports</i> , 2020, 6, 1316-1319.	0.4	2
18	Patient-reported quality of life in patients with relapsed/refractory cutaneous T-cell lymphoma: Results from the randomised phase III ALCANZA study. <i>European Journal of Cancer</i> , 2020, 133, 120-130.	1.3	21

#	ARTICLE	IF	CITATIONS
19	CD209 ⁺ monocyte-derived myeloid dendritic cells were increased in patients with leukemic cutaneous T-cell lymphoma undergoing extracorporeal photopheresis via the CELLEX TM system. <i>Photodermatology Photoimmunology and Photomedicine</i> , 2020, 36, 290-298.	0.7	4
20	Non-Classic Signs of SÅ©zary Syndrome: A Review. <i>American Journal of Clinical Dermatology</i> , 2020, 21, 383-391.	3.3	9
21	Second primary malignancies in blastic plasmacytoid dendritic cell neoplasm: A national database study. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1786-1789.	0.6	2
22	United States Cutaneous Lymphoma Consortium recommendations for treatment of cutaneous lymphomas during the COVID-19 pandemic. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 703-704.	0.6	22
23	Development of SÅ©zary syndrome following the administration of dupilumab. <i>Dermatology Online Journal</i> , 2020, 26, .	0.2	3
24	Anaphylaxis following administration of extracorporeal photopheresis for cutaneous T cell lymphoma. <i>Dermatology Online Journal</i> , 2020, 26, .	0.2	0
25	FINAL DATA FROM THE PHASE 3 ALCANZA STUDY: BRENTUXIMAB VEDOTIN (BV) VS PHYSICIAN'S CHOICE (PC) IN PATIENTS (PTS) WITH CD30-POSITIVE (CD30+) CUTANEOUS T-CELL LYMPHOMA (CTCL). <i>Hematological Oncology</i> , 2019, 37, 286-288.	0.8	2
26	Lichenoid dermatitis from immune checkpoint inhibitor therapy: An immune-related adverse event with mycosis fungoides-like morphologic and molecular features. <i>Journal of Cutaneous Pathology</i> , 2019, 46, 872-877.	0.7	4
27	Multi-institutional Investigation: Circulating CD4:CD8 ratio is a prognosticator of response to total skin electron beam radiation in mycosis fungoides. <i>Radiotherapy and Oncology</i> , 2019, 131, 88-92.	0.3	6
28	Long-term control of mycosis fungoides of the hands with topical bexarotene: an update 15 years later. <i>International Journal of Dermatology</i> , 2019, 58, e221-e222.	0.5	2
29	Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm. <i>New England Journal of Medicine</i> , 2019, 380, 1628-1637.	13.9	274
30	RESPONSE TO BRENTUXIMAB VEDOTIN BY CD30 EXPRESSION: RESULTS FROM FIVE TRIALS IN PTCL, CTCL, AND B-CELL LYMPHOMAS. <i>Hematological Oncology</i> , 2019, 37, 470-471.	0.8	2
31	Antibody-Based Therapies for Cutaneous T-Cell Lymphoma. <i>American Journal of Clinical Dermatology</i> , 2019, 20, 115-122.	3.3	21
32	Proteomic analysis of <i>stratum corneum</i> in Cutaneous T-cell Lymphomas and psoriasis. <i>Experimental Dermatology</i> , 2019, 28, 317-321.	1.4	8
33	Response to pembrolizumab and lenalidomide in advanced refractory mycosis fungoides. <i>Leukemia and Lymphoma</i> , 2019, 60, 1079-1082.	0.6	3
34	Primary cutaneous CD4+ small-to medium-sized pleomorphic T-cell lymphoproliferative disorder in a pediatric patient successfully treated with low-dose radiation. <i>Pediatric Dermatology</i> , 2019, 36, e23-e26.	0.5	4
35	Blood transcriptional profiling reveals IL-1 and integrin signaling pathways associated with clinical response to extracorporeal photopheresis in patients with leukemic cutaneous T-cell lymphoma. <i>Oncotarget</i> , 2019, 10, 3183-3197.	0.8	8
36	Nail irregularities associated with SÅ©zary syndrome. <i>Cutis</i> , 2019, 103, E11-E16.	0.4	2

#	ARTICLE	IF	CITATIONS
37	Waistband Mycosis Fungoides: A New Clinical Variant of Early-Stage Disease. <i>Skinmed</i> , 2019, 17, 329-332.	0.0	0
38	Necrotizing Granulomatous Dermatitis and Panniculitis Masquerading as T Cell Lymphoma. <i>Skinmed</i> , 2019, 17, 406-408.	0.0	1
39	Image Gallery: Symmetrical whirled eschars on the face in mycosis fungoides. <i>British Journal of Dermatology</i> , 2018, 178, e224-e224.	1.4	2
40	Childhood alopecia areata—Data from the National Alopecia Areata Registry. <i>Pediatric Dermatology</i> , 2018, 35, 164-169.	0.5	21
41	How to Discern Folliculotropic Mycosis Fungoides From Follicular Mucinosis Using a Pediatric Case. <i>Journal of Cutaneous Medicine and Surgery</i> , 2018, 22, 336-340.	0.6	14
42	Pruritic arthropod bite-like papules in T-cell large granular lymphocytic leukaemia and chronic myelomonocytic leukaemia. <i>Clinical and Experimental Dermatology</i> , 2018, 43, 449-453.	0.6	2
43	The Utility and Validity of the Alopecia Areata Symptom Impact Scale in Measuring Disease-Related Symptoms and their Effect on Functioning. <i>Journal of Investigative Dermatology Symposium Proceedings</i> , 2018, 19, S41-S46.	0.8	16
44	Mycosis fungoides occurring at the site of previous herpes zoster eruption. <i>Australasian Journal of Dermatology</i> , 2018, 59, 217-219.	0.4	4
45	Generalized morphea/eosinophilic fasciitis overlap after epoxy exposure. <i>JAAD Case Reports</i> , 2018, 4, 175-178.	0.4	2
46	The Use of Central Pathology Review With Digital Slide Scanning in Advanced-stage Mycosis Fungoides and S�azary Syndrome. <i>American Journal of Surgical Pathology</i> , 2018, 42, 726-734.	2.1	17
47	Alopecia areata is a medical disease. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 832-834.	0.6	38
48	Important considerations for legislation banning commercial tanning beds among minors. <i>Clinics in Dermatology</i> , 2018, 36, 104-105.	0.8	0
49	Differential expression of CCR4 in primary cutaneous gamma/delta (���) T cell lymphomas and mycosis fungoides: Significance for diagnosis and therapy. <i>Journal of Dermatological Science</i> , 2018, 89, 88-91.	1.0	13
50	Responses to romidepsin in patients with cutaneous T-cell lymphoma and prior treatment with systemic chemotherapy. <i>Leukemia and Lymphoma</i> , 2018, 59, 880-887.	0.6	28
51	Alternate dosing regimens of brentuximab vedotin for CD 30+ cutaneous T�cell lymphoma. <i>British Journal of Dermatology</i> , 2018, 178, 302-303.	1.4	4
52	Juvenile mycosis fungoides with large�cell transformation: Successful treatment with psoralen with ultraviolet A light, interferon�alfa, and localized radiation. <i>Pediatric Dermatology</i> , 2018, 35, e13-e16.	0.5	3
53	The �Duvic regimen�for erythrodermic flares secondary to <i>Staphylococcus aureus</i> in mycosis fungoides and S�azary syndrome. <i>International Journal of Dermatology</i> , 2018, 57, 123-124.	0.5	18
54	Radiotherapy in Patients with Mycosis Fungoides and Central Nervous System Involvement. <i>Case Reports in Oncology</i> , 2018, 11, 721-728.	0.3	1

#	ARTICLE	IF	CITATIONS
55	Inflammatory cytokines and peripheral mediators in the pathophysiology of pruritus in cutaneous T-cell lymphoma. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 1652-1656.	1.3	20
56	Gene expression profiling and immune cell-type deconvolution highlight robust disease progression and survival markers in multiple cohorts of CTCL patients. <i>Oncolmmunology</i> , 2018, 7, e1467856.	2.1	24
57	Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 1192-1204.	5.1	398
58	Cobomarsen, an oligonucleotide inhibitor of miR-155, coordinately regulates multiple survival pathways to reduce cellular proliferation and survival in cutaneous T-cell lymphoma. <i>British Journal of Haematology</i> , 2018, 183, 428-444.	1.2	219
59	High-throughput T cell receptor sequencing identifies clonally expanded CD8+ T cell populations in alopecia areata. <i>JCI Insight</i> , 2018, 3, .	2.3	42
60	Complete resolution of mycosis fungoides tumors with imiquimod 5% cream: a case series. <i>Journal of Dermatological Treatment</i> , 2017, 28, 567-569.	1.1	20
61	Results from a Phase I/II Open-Label, Dose-Finding Study of Pralatrexate and Oral Bexarotene in Patients with Relapsed/Refractory Cutaneous T-cell Lymphoma. <i>Clinical Cancer Research</i> , 2017, 23, 3552-3556.	3.2	20
62	Immunophenotypic Shifts in Primary Cutaneous $\hat{\gamma}$ T-Cell Lymphoma Suggest Antigenic Modulation. <i>American Journal of Surgical Pathology</i> , 2017, 41, 431-445.	2.1	12
63	Forodesine in the treatment of cutaneous T-cell lymphoma. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 771-775.	1.9	8
64	Gene expression analysis in Cutaneous T-Cell Lymphomas (CTCL) highlights disease heterogeneity and potential diagnostic and prognostic indicators. <i>Oncolmmunology</i> , 2017, 6, e1306618.	2.1	78
65	Clinical characteristics, risk factors and long-term outcome of 114 patients with folliculotropic mycosis fungoides. <i>Archives of Dermatological Research</i> , 2017, 309, 453-459.	1.1	32
66	Primary Cutaneous T-Cell Lymphomas Showing Gamma-Delta ($\hat{\gamma}$) Phenotype and Predominantly Epidermotropic Pattern are Clinicopathologically Distinct From Classic Primary Cutaneous $\hat{\gamma}$ T-Cell Lymphomas. <i>American Journal of Surgical Pathology</i> , 2017, 41, 204-215.	2.1	57
67	Effectiveness of low-dose radiation for primary cutaneous anaplastic large cell lymphoma. <i>Advances in Radiation Oncology</i> , 2017, 2, 363-369.	0.6	9
68	Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. <i>Lancet</i> , The, 2017, 390, 555-566.	6.3	444
69	Extracorporeal photopheresis for the treatment of early-stage mycosis fungoides. <i>Dermatologic Therapy</i> , 2017, 30, e12485.	0.8	6
70	Brentuximab Vedotin for Patients With Refractory Lymphomatoid Papulosis. <i>JAMA Dermatology</i> , 2017, 153, 1302.	2.0	28
71	Generalised Eruptive Keratoacanthomas of Grzybowski. <i>Journal of Cutaneous Medicine and Surgery</i> , 2017, 21, 439-439.	0.6	0
72	Primary Cutaneous Peripheral T-Cell Lymphoma in a Sporotrichoid Pattern: A Case Report. <i>Journal of Cutaneous Medicine and Surgery</i> , 2017, 21, 568-571.	0.6	1

#	ARTICLE	IF	CITATIONS
73	BRENTUXIMAB VEDOTIN VS PHYSICIAN'S CHOICE IN CTCL PATIENTS FROM THE PHASE 3 ALCANZA STUDY: ANALYSIS OF OUTCOMES BY CD30 EXPRESSION. <i>Hematological Oncology</i> , 2017, 35, 77-78.	0.8	2
74	Oral bexarotene for post-transplant cutaneous T-cell lymphoma. <i>Dermatologic Therapy</i> , 2017, 30, e12524.	0.8	6
75	Mogamulizumab for the treatment of relapsed or refractory adult T-cell leukemia-lymphoma. <i>Expert Review of Hematology</i> , 2017, 10, 757-760.	1.0	6
76	A possible association between mycosis fungoides and Muir-Torre syndrome: Two disorders with microsatellite instability. <i>JAAD Case Reports</i> , 2017, 3, 358-361.	0.4	1
77	RESPONSE BY STAGE IN CD30-POSITIVE (CD30+) CUTANEOUS T CELL LYMPHOMA (CTCL) PATIENTS RECEIVING BRENTUXIMAB VEDOTIN (BV) VS PHYSICIAN'S CHOICE (PC) IN THE PHASE 3 ALCANZA STUDY. <i>Hematological Oncology</i> , 2017, 35, 245-247.	0.8	1
78	PATIENT-REPORTED OUTCOMES AND QUALITY OF LIFE IN PATIENTS WITH CUTANEOUS T CELL LYMPHOMA: RESULTS FROM THE PHASE 3 ALCANZA STUDY. <i>Hematological Oncology</i> , 2017, 35, 247-248.	0.8	2
79	An adolescent with granulomatous mycosis fungoides infiltrating skeletal muscle successfully treated with oral prednisone. <i>JAAD Case Reports</i> , 2017, 3, 276-279.	0.4	3
80	Diverse types of dermatologic toxicities from immune checkpoint blockade therapy. <i>Journal of Cutaneous Pathology</i> , 2017, 44, 158-176.	0.7	186
81	Essential Role of DNA Methyltransferase 1-mediated Transcription of Insulin-like Growth Factor 2 in Resistance to Histone Deacetylase Inhibitors. <i>Clinical Cancer Research</i> , 2017, 23, 1299-1311.	3.2	24
82	Primary cutaneous anaplastic large-cell lymphoma: Complete remission for 13 years after denileukin diftitox. <i>JAAD Case Reports</i> , 2017, 3, 501-504.	0.4	16
83	Recent advances in systemic targeted therapy for cutaneous T-cell lymphoma. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1535-1536.	0.9	4
84	Novel Mutations Involving NF- κ B and B-Cell Signaling Pathways in Primary Cutaneous Large B-Cell Lymphoma, Leg-Type and Comparison with SA \odot zary Syndrome. <i>Journal of Investigative Dermatology</i> , 2017, 137, 1831-1833.	0.3	6
85	TruSeq-Based Gene Expression Analysis of Formalin-Fixed Paraffin-Embedded (FFPE) Cutaneous T-Cell Lymphoma Samples: Subgroup Analysis Results and Elucidation of Biases from FFPE Sample Processing on the TruSeq Platform. <i>Frontiers in Medicine</i> , 2017, 4, 153.	1.2	16
86	Curcumin for the treatment of tumor-stage mycosis fungoides. <i>Dermatologic Therapy</i> , 2017, 30, e12511.	0.8	7
87	ONC201 selectively induces apoptosis in cutaneous T-cell lymphoma cells via activating pro-apoptotic integrated stress response and inactivating JAK/STAT and NF- κ B pathways. <i>Oncotarget</i> , 2017, 8, 61761-61776.	0.8	26
88	Mycosis Fungoides of the Oral Cavity: Fungating Tumor Successfully Treated with Electron Beam Radiation and Maintenance Bexarotene. <i>Case Reports in Dermatological Medicine</i> , 2016, 2016, 1-7.	0.1	7
89	A case of indeterminate dendritic cell tumor presenting with leonine facies. <i>Journal of Cutaneous Pathology</i> , 2016, 43, 158-163.	0.7	12
90	Scleromyxedema: long-term follow-up after high-dose melphalan with autologous stem cell transplantation. <i>International Journal of Dermatology</i> , 2016, 55, e539-43.	0.5	16

#	ARTICLE	IF	CITATIONS
91	Molecular signatures define alopecia areata subtypes and transcriptional biomarkers. <i>EBioMedicine</i> , 2016, 7, 240-247.	2.7	70
92	Lymphomatoid Papulosis in Children and Adolescents: A Systematic Review. <i>American Journal of Clinical Dermatology</i> , 2016, 17, 319-327.	3.3	44
93	Clinical Efficacy of Romidepsin in Tumor Stage and Folliculotropic Mycosis Fungoides. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 637-643.	0.2	19
94	Primary cutaneous CD30 ⁺ lymphoproliferative disorders. <i>JDDG - Journal of the German Society of Dermatology</i> , 2016, 14, 767-782.	0.4	12
95	Clinicopathological and molecular study of primary cutaneous CD4+ small/medium-sized pleomorphic T-cell lymphoma. <i>Journal of Cutaneous Pathology</i> , 2016, 43, 1121-1130.	0.7	34
96	Loss of CD30 expression after treatment with brentuximab vedotin in a patient with anaplastic large cell lymphoma: a novel finding. <i>Journal of Cutaneous Pathology</i> , 2016, 43, 1161-1166.	0.7	40
97	Primär kutane CD30 ⁺ lymphoproliferative Erkrankungen. <i>JDDG - Journal of the German Society of Dermatology</i> , 2016, 14, 767-784.	0.4	8
98	Mogamulizumab in the treatment of cutaneous T cell lymphoma. <i>Expert Opinion on Orphan Drugs</i> , 2016, 4, 1277-1280.	0.5	0
99	Granulomatous Mycosis Fungoides in an Adolescent – A Rare Encounter and Review of the Literature. <i>Pediatric Dermatology</i> , 2016, 33, e296-8.	0.5	8
100	Mogamulizumab for the treatment of cutaneous T-cell lymphoma: recent advances and clinical potential. <i>Therapeutic Advances in Hematology</i> , 2016, 7, 171-174.	1.1	36
101	miR-63/DGCR8-Dependent MicroRNAs Mediate Therapeutic Efficacy of HDAC Inhibitors in Cancer. <i>Cancer Cell</i> , 2016, 29, 874-888.	7.7	32
102	Investigating potential exogenous tumor initiating and promoting factors for Cutaneous T-Cell Lymphomas (CTCL), a rare skin malignancy. <i>Oncolmmunology</i> , 2016, 5, e1175799.	2.1	36
103	BRAF inhibitor therapy-associated melanocytic lesions lack the BRAF V600E mutation and show increased levels of cyclin D1 expression. <i>Human Pathology</i> , 2016, 50, 79-89.	1.1	18
104	Lymphomatoid papulosis: Treatment response and associated lymphomas in a study of 180 patients. <i>Journal of the American Academy of Dermatology</i> , 2016, 74, 59-67.	0.6	96
105	Retrospective Analysis of Prognostic Factors in 187 Cases of Transformed Mycosis Fungoides. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 49-56.	0.2	44
106	A Single-Center Experience With Brentuximab Vedotin in Gamma Delta T-Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, e15-e19.	0.2	16
107	The safety profile of vorinostat (suberoylanilide hydroxamic acid) in hematologic malignancies: A review of clinical studies. <i>Cancer Treatment Reviews</i> , 2016, 43, 58-66.	3.4	51
108	Brentuximab Vedotin Demonstrates Significantly Superior Clinical Outcomes in Patients with CD30-Expressing Cutaneous T Cell Lymphoma Versus Physician's Choice (Methotrexate or Bexarotene): The Phase 3 Alcanza Study. <i>Blood</i> , 2016, 128, 182-182.	0.6	12

#	ARTICLE	IF	CITATIONS
109	First-in-Human, Multicenter Phase I Study of IPH4102, First-in-Class Humanized Anti-KIR3DL2 Monoclonal Antibody, in Relapsed/Refractory Cutaneous T-Cell Lymphomas: Preliminary Safety, Exploratory and Clinical Activity Results. <i>Blood</i> , 2016, 128, 1826-1826.	0.6	6
110	Cutaneous T-cell lymphoma in a patient with celiac disease. <i>Cutis</i> , 2016, 98, E1-2.	0.4	0
111	Reed syndrome presenting with leiomyosarcoma. <i>JAAD Case Reports</i> , 2015, 1, 150-152.	0.4	16
112	Choosing a systemic treatment for advanced stage cutaneous T-cell lymphoma: mycosis fungoides and SÅ©zary syndrome. <i>Hematology American Society of Hematology Education Program</i> , 2015, 2015, 529-544.	0.9	14
113	Demographic patterns of cutaneous Tâ€cell lymphoma incidence in Texas based on two different cancer registries. <i>Cancer Medicine</i> , 2015, 4, 1440-1447.	1.3	44
114	Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma. <i>Blood</i> , 2015, 125, 1883-1889.	0.6	203
115	The effect of extracorporeal photopheresis alone or in combination therapy on circulating <sc>CD</sc>4⁺Fxp3⁺<sc>CD</sc>25^{âˆ²} T cells in patients with leukemic cutaneous Tâ€cell lymphoma. <i>Photodermatology Photoimmunology and Photomedicine</i> , 2015, 31, 184-194.	0.7	15
116	A Phase <sc>II</sc> trial of Belinostat (<sc>PXD</sc>101) in patients with relapsed or refractory peripheral or cutaneous Tâ€cell lymphoma. <i>British Journal of Haematology</i> , 2015, 168, 811-819.	1.2	172
117	Low-dose total skin electron beam therapy as an effective modality to reduce disease burden in patients with mycosis fungoides: Results of a pooled analysis from 3 phase-II clinical trials. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 286-292.	0.6	156
118	Characteristics of Sweet Syndrome in Patients With Acute Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 358-363.	0.2	50
119	An unusual case of cytotoxic peripheral T-cell lymphoma. <i>JAAD Case Reports</i> , 2015, 1, 257-260.	0.4	4
120	Identification of geographic clustering and regions spared by cutaneous Tâ€cell lymphoma in Texas using 2 distinct cancer registries. <i>Cancer</i> , 2015, 121, 1993-2003.	2.0	45
121	Advanced-Stage Mycosis Fungoides and SÅ©zary Syndrome: Survival and Response to Treatment. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, e105-e112.	0.2	35
122	Clinically significant responses achieved with romidepsin across disease compartments in patients with cutaneous T-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 2847-2854.	0.6	17
123	Shared clonality in distinctive lesions of lymphomatoid papulosis and mycosis fungoides occurring in the same patients suggests a common origin. <i>Human Pathology</i> , 2015, 46, 558-569.	1.1	43
124	Histone Deacetylase Inhibitors for Cutaneous T-Cell Lymphoma. <i>Dermatologic Clinics</i> , 2015, 33, 757-764.	1.0	32
125	Results of a Phase II Trial of Brentuximab Vedotin for CD30⁺ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis. <i>Journal of Clinical Oncology</i> , 2015, 33, 3759-3765.	0.8	255
126	Depletion of regulatory T cells by targeting CC chemokine receptor type 4 with mogamulizumab. <i>Oncolmmunology</i> , 2015, 4, e1011524.	2.1	34

#	ARTICLE	IF	CITATIONS
127	Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Szary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model. <i>Journal of Clinical Oncology</i> , 2015, 33, 3766-3773.	0.8	328
128	Resimmune, an anti-CD3 recombinant immunotoxin, induces durable remissions in patients with cutaneous T-cell lymphoma. <i>Haematologica</i> , 2015, 100, 794-800.	1.7	46
129	Leonine facies (LF) and mycosis fungoides (MF): A single-center study and systematic review of the literature. <i>Journal of the American Academy of Dermatology</i> , 2015, 73, 976-986.	0.6	22
130	Allogeneic stem-cell transplantation in patients with cutaneous lymphoma: updated results from a single institution. <i>Annals of Oncology</i> , 2015, 26, 2490-2495.	0.6	87
131	Genomic profiling of Szary syndrome identifies alterations of key T cell signaling and differentiation genes. <i>Nature Genetics</i> , 2015, 47, 1426-1434.	9.4	276
132	Long-Term Complete Responses to Combination Therapies and Allogeneic Stem Cell Transplants in Patients With Szary Syndrome. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, e83-e93.	0.2	37
133	Lymphomatoid Papulosis: Assessing Treatment Response and Associated Lymphomas in a Study of 180 Patients. <i>Blood</i> , 2015, 126, 1487-1487.	0.6	0
134	Blood Transcriptional Profiling in Patients with Leukemic Cutaneous T-Cell Lymphoma on Extracorporeal Photopheresis Reveals the Integrin Signaling As the Top Pathway Associated with Clinical Response. <i>Blood</i> , 2015, 126, 3981-3981.	0.6	0
135	Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous t-cell lymphomas (CTCL) (Mycosis fungoides and Tj ETQq1 1 0.784314 rgBTj/Overlo	0.6	0
136	Szary syndrome: an overview of current and future treatment options. <i>Expert Opinion on Orphan Drugs</i> , 2014, 2, 889-901.	0.5	0
137	Concurrent chronic lymphocytic leukemia and cutaneous T cell lymphoma: a case series. <i>Leukemia and Lymphoma</i> , 2014, 55, 2192-2195.	0.6	1
138	Mechlorethamine gel for the topical treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma. <i>Expert Review of Clinical Pharmacology</i> , 2014, 7, 591-597.	1.3	22
139	Deregulation in STAT signaling is important for cutaneous T-cell lymphoma (CTCL) pathogenesis and cancer progression. <i>Cell Cycle</i> , 2014, 13, 3331-3335.	1.3	103
140	Vitamin D Deficiency in Mycosis Fungoides and Szary Syndrome Patients Is Similar to Other Cancer Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 518-524.	0.2	21
141	T-Cell Receptor- in Gamma-Delta Phenotype Cutaneous T-Cell Lymphoma Can Be Accompanied by Atypical Expression of CD30, CD4, or TCRF1 and an Indolent Clinical Course. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, e195-e200.	0.2	14
142	Clinical presentation, immunopathology, and treatment of juvenile-onset mycosis fungoides: A case series of 34 patients. <i>Journal of the American Academy of Dermatology</i> , 2014, 71, 1117-1126.	0.6	71
143	Alopecia areata after HLA-identical BMT from an affected, sibling donor. <i>Bone Marrow Transplantation</i> , 2014, 49, 592-594.	1.3	4
144	Interferon-Based Treatment for Patients with Mycosis Fungoides and Hepatitis Virus Infection: ACase Series. <i>American Journal of Clinical Dermatology</i> , 2014, 15, 451-456.	3.3	3

#	ARTICLE	IF	CITATIONS
145	Pralatrexate Alone or in Combination With Bexarotene: Long-Term Tolerability in Relapsed/Refractory Mycosis Fungoides. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 297-304.	0.2	16
146	Results of an open-label multicenter phase 2 trial of lenalidomide monotherapy in refractory mycosis fungoides and S�zary syndrome. <i>Blood</i> , 2014, 123, 1159-1166.	0.6	76
147	A case of invisible leukemic cutaneous T�fcell lymphoma with a regulatory T�fcell clone. <i>International Journal of Dermatology</i> , 2013, 52, 1111-1114.	0.5	12
148	A cutaneous lymphoma international prognostic index (CLIPi) for mycosis fungoides and Sezary syndrome. <i>European Journal of Cancer</i> , 2013, 49, 2859-2868.	1.3	121
149	Duration of Response in Cutaneous T-Cell Lymphoma Patients Treated With Denileukin Diftitox: Results From 3 Phase III Studies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 377-384.	0.2	35
150	Denileukin diftitox for the treatment of CD25 low-expression mycosis fungoides and S�zary syndrome. <i>Leukemia and Lymphoma</i> , 2013, 54, 69-75.	0.6	22
151	Clinically meaningful reduction in pruritus in patients with cutaneous T-cell lymphoma treated with romidepsin. <i>Leukemia and Lymphoma</i> , 2013, 54, 284-289.	0.6	36
152	Panobinostat activity in both bexarotene-exposed and -na�ve patients with refractory cutaneous T-cell lymphoma: Results of a phase II trial. <i>European Journal of Cancer</i> , 2013, 49, 386-394.	1.3	124
153	Papuloerythroderma of Ofuji associated with an indolent CD3(�), CD4(+), TCR(�) peripheral T-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2013, 54, 2059-2061.	0.6	3
154	Hydrochlorothiazide and cutaneous T cell lymphoma. <i>Cancer</i> , 2013, 119, 825-831.	2.0	57
155	Efficacy and safety of denileukin diftitox retreatment in patients with relapsed cutaneous T-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2013, 54, 514-519.	0.6	13
156	Augmentation of Blood Dendritic Cells by Extracorporeal Photopheresis in Patients with Leukemic Cutaneous T-Cell Lymphoma and Graft-Versus-Host Disease. <i>Journal of Investigative Dermatology</i> , 2013, 133, 2098-2100.	0.3	20
157	The National Alopecia Areata Registry�Update. <i>Journal of Investigative Dermatology Symposium Proceedings</i> , 2013, 16, S53.	0.8	6
158	Primary cutaneous follicle center lymphoma following deep brain stimulation implants. <i>Leukemia and Lymphoma</i> , 2013, 54, 1806-1807.	0.6	0
159	Cutaneous T-Cell Lymphomas: Mycosis Fungoides and S�zary Syndrome. , 2013, , 287-329.		2
160	Cutaneous T-Cell Lymphomas. , 2013, , 155-177.		0
161	Trends in the treatment of cutaneous T-cell lymphoma – critical evaluation and perspectives on vorinostat. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2012, , 17.	1.2	2
162	Cutaneous �T-cell Lymphomas. <i>American Journal of Surgical Pathology</i> , 2012, 36, 1656-1665.	2.1	154

#	ARTICLE	IF	CITATIONS
163	Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma. <i>Blood</i> , 2012, 119, 4115-4122.	0.6	122
164	Long-term follow-up and survival of cutaneous T-cell lymphoma patients treated with extracorporeal photopheresis. <i>Photodermatology Photoimmunology and Photomedicine</i> , 2012, 28, 250-257.	0.7	41
165	HDAC inhibitors for the treatment of cutaneous T-cell lymphomas. <i>Future Medicinal Chemistry</i> , 2012, 4, 471-486.	1.1	61
166	Long-term Outcomes of 1,263 Patients with Mycosis Fungoides and S�zary Syndrome from 1982 to 2009. <i>Clinical Cancer Research</i> , 2012, 18, 5051-5060.	3.2	245
167	Incidence of spontaneous remission in patients with CD25-positive mycosis fungoides/S�zary syndrome receiving placebo. <i>Journal of the American Academy of Dermatology</i> , 2012, 67, 867-875.	0.6	18
168	Pilot Study of Denileukin Diftitox Alternate Dosing Regimen in Patients With Cutaneous Peripheral T-Cell Lymphomas. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2012, 12, 180-185.	0.2	12
169	Increased Twist expression in advanced stage of mycosis fungoides and S�zary syndrome. <i>Journal of Cutaneous Pathology</i> , 2012, 39, 500-507.	0.7	28
170	Prevalence and severity of pruritus in cutaneous T cell lymphoma. <i>International Journal of Dermatology</i> , 2012, 51, 930-934.	0.5	68
171	Multicenter Photopheresis Intervention Trial in Early-Stage Mycosis Fungoides. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 219-227.	0.2	41
172	Treatment of Cutaneous Lymphoid Hyperplasia with the Monoclonal Anti-CD20 Antibody Rituximab. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 286-288.	0.2	19
173	The spectrum of hair loss in patients with mycosis fungoides and S�zary syndrome. <i>Journal of the American Academy of Dermatology</i> , 2011, 64, 53-63.	0.6	46
174	S�zary syndrome: Immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC). <i>Journal of the American Academy of Dermatology</i> , 2011, 64, 352-404.	0.6	154
175	CO26. Results of a phase 1/2 study for KW-0761, a monoclonal antibody directed against CC chemokine receptor type 4 (CCR4), in CTCL patients. <i>Melanoma Research</i> , 2011, 21, e15-e16.	0.6	3
176	S�zary syndrome cells overexpress syndecan-4 bearing distinct heparan sulfate moieties that suppress T-cell activation by binding DC-HIL and trapping TGF-�2 on the cell surface. <i>Blood</i> , 2011, 117, 3382-3390.	0.6	33
177	EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma*. <i>Blood</i> , 2011, 118, 4024-4035.	0.6	365
178	CD30+ Neoplasms of the Skin. <i>Current Hematologic Malignancy Reports</i> , 2011, 6, 245-250.	1.2	64
179	Predictors of complete responses with denileukin diftitox in cutaneous T-cell lymphoma. <i>American Journal of Hematology</i> , 2011, 86, 627-630.	2.0	10
180	Clinical End Points and Response Criteria in Mycosis Fungoides and S�zary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 2598-2607.	0.8	550

#	ARTICLE	IF	CITATIONS
181	Phase II Multicenter Trial of Lenalidomide: Clinical and Immunomodulatory Effects in Patients with CTCL. <i>Blood</i> , 2011, 118, 1638-1638.	0.6	3
182	Dendritic cells and cutaneous T-cell lymphomas. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2011, 146, 103-13.	0.8	8
183	Serum T helper 1 cytokine levels are greater in patients with alopecia areata regardless of severity or atopy. <i>Clinical and Experimental Dermatology</i> , 2010, 35, 409-416.	0.6	57
184	Genome-wide association study in alopecia areata implicates both innate and adaptive immunity. <i>Nature</i> , 2010, 466, 113-117.	13.7	651
185	Vorinostat for the treatment of cutaneous T-cell lymphoma. <i>Expert Review of Dermatology</i> , 2010, 5, 393-401.	0.3	1
186	Total Skin Electron Beam and Non-Myeloablative Allogeneic Hematopoietic Stem-Cell Transplantation in Advanced Mycosis Fungoides and SÅ©zary Syndrome. <i>Journal of Clinical Oncology</i> , 2010, 28, 2365-2372.	0.8	149
187	Curcumin Selectively Induces Apoptosis in Cutaneous T-Cell Lymphoma Cell Lines and Patientsâ€™ PBMCs: Potential Role for STAT-3 and NF-Î²B Signaling. <i>Journal of Investigative Dermatology</i> , 2010, 130, 2110-2119.	0.3	96
188	Rational Clinical Trial Design in Cutaneous Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, S80-S83.	0.2	0
189	Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma. <i>Journal of the American Academy of Dermatology</i> , 2010, 63, 975-983.	0.6	90
190	Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2010, 28, 4485-4491.	0.8	604
191	HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 6532-6537.	3.3	141
192	Phase III Placebo-Controlled Trial of Denileukin Diftitox for Patients With Cutaneous T-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2010, 28, 1870-1877.	0.8	212
193	Primary and Metastatic Malignant Tumors of the Scalp. <i>American Journal of Clinical Dermatology</i> , 2010, 11, 1.	3.3	20
194	A Phase II Study of SGN-30 in Cutaneous Anaplastic Large Cell Lymphoma and Related Lymphoproliferative Disorders. <i>Clinical Cancer Research</i> , 2009, 15, 6217-6224.	3.2	84
195	Detection of high-risk human papillomaviruses in verrucae of patients with mycosis fungoides and SÅ©zary syndrome: a case series. <i>International Journal of Dermatology</i> , 2009, 48, 598-602.	0.5	7
196	Overall survival in erythrodermic cutaneous Tâ€cell lymphoma: an analysis of prognostic factors in a cohort of patients with erythrodermic cutaneous Tâ€cell lymphoma. <i>International Journal of Dermatology</i> , 2009, 48, 243-252.	0.5	108
197	Lymphomatoid papulosis and associated lymphomas: a retrospective case series of 84 patients. <i>Clinical and Experimental Dermatology</i> , 2009, 34, 576-581.	0.6	89
198	Poor prognosis in non-Caucasian patients with early-onset mycosis fungoides. <i>Journal of the American Academy of Dermatology</i> , 2009, 60, 231-235.	0.6	79

#	ARTICLE	IF	CITATIONS
199	History of atopy or autoimmunity increases risk of alopecia areata. <i>Journal of the American Academy of Dermatology</i> , 2009, 61, 581-591.	0.6	160
200	Evaluation of the Long-Term Tolerability and Clinical Benefit of Vorinostat in Patients With Advanced Cutaneous T-Cell Lymphoma. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, 412-416.	1.4	88
201	Efficacy and safety of topical tazarotene: a review. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2009, 5, 195-210.	1.5	22
202	Relationship between efficacy of denileukin diftitox (Dd) and antibody development in cutaneous T-cell lymphoma (CTCL): An analysis of two phase III studies. <i>Journal of Clinical Oncology</i> , 2009, 27, e19534-e19534.	0.8	0
203	Molecular and Biological Characteristics of Acquired Vorinostat-Resistant Cutaneous T-Cell Lymphoma Cells. <i>Blood</i> , 2009, 114, 1732-1732.	0.6	0
204	Primary Sezary Syndrome Commonly Involves Skin Without Epidermotropism. <i>Journal of Cutaneous Pathology</i> , 2008, 32, 85-85.	0.7	0
205	Induction of T-Cell Responses against Cutaneous T-Cell Lymphomas Ex Vivo by Autologous Dendritic Cells Transfected with Amplified Tumor mRNA. <i>Journal of Investigative Dermatology</i> , 2008, 128, 2631-2639.	0.3	23
206	Avicin D Selectively Induces Apoptosis and Downregulates p-STAT-3, bcl-2, and Survivin in Cutaneous T-Cell Lymphoma Cells. <i>Journal of Investigative Dermatology</i> , 2008, 128, 2728-2735.	0.3	40
207	Human Leukocyte Antigen Class II Alleles Are Associated with Risk of Alopecia Areata. <i>Journal of Investigative Dermatology</i> , 2008, 128, 240-243.	0.3	26
208	Prevalence and treatment of Staphylococcus aureus colonization in patients with mycosis fungoides and S�azary syndrome. <i>British Journal of Dermatology</i> , 2008, 159, 105-112.	1.4	167
209	Cutaneous �� T-Cell Lymphoma Treated with Radiation and Denileukin Diftitox. <i>Clinical Lymphoma and Myeloma</i> , 2008, 8, 55-58.	1.4	16
210	Increased Malignancy Risk in the Cutaneous T-Cell Lymphoma Patient Population. <i>Clinical Lymphoma and Myeloma</i> , 2008, 8, 100-105.	1.4	35
211	Novel treatments for cutaneous T-cell lymphomas. <i>Annales De Dermatologie Et De Venereologie</i> , 2008, 135, A25-A26.	0.5	0
212	Central nervous system involvement in patients with mycosis fungoides and cutaneous large-cell transformation. <i>Journal of the American Academy of Dermatology</i> , 2008, 59, S16-S22.	0.6	20
213	EGFR Inhibitor-Associated Acneiform Folliculitis. <i>American Journal of Clinical Dermatology</i> , 2008, 9, 285-294.	3.3	30
214	Optimizing denileukin diftitox (Ontak [�]) therapy. <i>Future Oncology</i> , 2008, 4, 457-469.	1.1	55
215	Review of the Treatment of Mycosis Fungoides and S�azary Syndrome: A Stage-Based Approach. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2008, 6, 436-442.	2.3	123
216	Skin directed therapy for mycosis fungoides: a review. <i>Journal of Drugs in Dermatology</i> , 2008, 7, 655-66.	0.4	28

#	ARTICLE	IF	CITATIONS
217	Treatment of Transformed Mycosis Fungoides with Intermittent Low-Dose Gemcitabine. <i>Oncology</i> , 2007, 73, 130-135.	0.9	11
218	Phase IIB Multicenter Trial of Vorinostat in Patients With Persistent, Progressive, or Treatment Refractory Cutaneous T-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2007, 25, 3109-3115.	0.8	972
219	Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). <i>Blood</i> , 2007, 109, 31-39.	0.6	1,056
220	Lesional gene expression profiling in cutaneous T-cell lymphoma reveals natural clusters associated with disease outcome. <i>Blood</i> , 2007, 110, 3015-3027.	0.6	115
221	Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. <i>Blood</i> , 2007, 109, 4655-4662.	0.6	200
222	Revisions to the staging and classification of mycosis fungoides and SÅ©zary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). <i>Blood</i> , 2007, 110, 1713-1722.	0.6	1,243
223	Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. <i>Expert Opinion on Investigational Drugs</i> , 2007, 16, 1111-1120.	1.9	289
224	Coexistent Psoriasis and Lupus Erythematosus Treated with Alefacept. <i>American Journal of Clinical Dermatology</i> , 2007, 8, 47-50.	3.3	10
225	Pulmonary manifestations in patients with cutaneous T-cell lymphomas. <i>Cancer</i> , 2007, 109, 1550-1555.	2.0	22
226	The optimal use of bexarotene in cutaneous T-cell lymphoma. <i>British Journal of Dermatology</i> , 2007, 157, 433-440.	1.4	150
227	Mycosis Fungoides: Pathophysiology and Emerging Therapies. <i>Seminars in Oncology</i> , 2007, 34, S21-S28.	0.8	37
228	Activation of HIV in Human Skin by Ultraviolet B Radiation and its Inhibition by NFÎ¸B Blocking Agents. <i>Photochemistry and Photobiology</i> , 2007, 74, 805-810.	1.3	2
229	Vorinostat in cutaneous T-cell lymphoma. <i>Drugs of Today</i> , 2007, 43, 585.	0.7	51
230	Retinoids in Cutaneous T-Cell Lymphomas. <i>Basic and Clinical Dermatology</i> , 2007, , 183-196.	0.1	1
231	Overall Survival in Erythrodermic Cutaneous T-Cell Lymphoma: An Analysis of Prognostic Factors in a Cohort of Erythrodermic Cutaneous T-Cell Lymphoma Patients.. <i>Blood</i> , 2007, 110, 3574-3574.	0.6	0
232	Update on the treatment of cutaneous T-cell lymphoma (CTCL): Focus on vorinostat. <i>Biologics: Targets and Therapy</i> , 2007, 1, 377-92.	3.0	33
233	Systemic monotherapy vs combination therapy for CTCL: rationale and future strategies. <i>Oncology</i> , 2007, 21, 33-40.	0.4	10
234	Photopheresis versus transimmunization?. <i>Leukemia and Lymphoma</i> , 2006, 47, 1449-1449.	0.6	2

#	ARTICLE	IF	CITATIONS
235	Treatment of Mycosis Fungoides with Denileukin Diftitox and Oral Bexarotene. <i>Clinical Lymphoma and Myeloma</i> , 2006, 6, 488-492.	1.4	8
236	Phase II Evaluation of Gemcitabine Monotherapy for Cutaneous T-Cell Lymphoma. <i>Clinical Lymphoma and Myeloma</i> , 2006, 7, 51-58.	1.4	137
237	Mycosis Fungoides with Coccidioidomycosis. <i>Clinical Lymphoma and Myeloma</i> , 2006, 7, 148-150.	1.4	6
238	A phase II open-label study of recombinant human interleukin-12 in patients with stage IA, IB, or IIA mycosis fungoides. <i>Journal of the American Academy of Dermatology</i> , 2006, 55, 807-813.	0.6	65
239	High flotillin-2 expression is associated with lymph node metastasis and Breslow depth in melanoma. <i>Melanoma Research</i> , 2006, 16, 461-463.	0.6	27
240	Treatment of cutaneous T-cell lymphoma with retinoids. <i>Dermatologic Therapy</i> , 2006, 19, 264-271.	0.8	73
241	Clinical and laboratory experience of vorinostat (suberoylanilide hydroxamic acid) in the treatment of cutaneous T-cell lymphoma. <i>British Journal of Cancer</i> , 2006, 95, S13-S19.	2.9	30
242	CD25 Expression Is Correlated with Histological Grade and Response to Denileukin Diftitox in Cutaneous T-Cell Lymphoma. <i>Journal of Investigative Dermatology</i> , 2006, 126, 575-583.	0.3	96
243	Thyrotoxicosis after Denileukin Diftitox Therapy in Patients with Mycosis Fungoides. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 2205-2208.	1.8	30
244	Oral Forodesine (Bcx-1777) Is Clinically Active in Refractory Cutaneous T-Cell Lymphoma: Results of a Phase I/II Study. <i>Blood</i> , 2006, 108, 2467-2467.	0.6	12
245	Vorinostat (suberoylanilide hydroxamic acid, SAHA) is clinically active in advanced cutaneous T-cell lymphoma (CTCL): Results of a phase IIb trial. <i>Journal of Clinical Oncology</i> , 2006, 24, 7500-7500.	0.8	24
246	Induction of Polyclonal T-Cell Responses Against Cutaneous T-Cell Lymphomas by Autologous Dendritic Cells Transfected with Amplified Tumor RNA. <i>Blood</i> , 2006, 108, 5189-5189.	0.6	0
247	Resistance to Activation-Induced Cell Death and Bystander Cytotoxicity Via the Fas/Fas Ligand Pathway Are Implicated in the Pathogenesis of Cutaneous T Cell Lymphomas. <i>Journal of Investigative Dermatology</i> , 2005, 124, 741-750.	0.3	42
248	Selective Induction of Apoptosis by Histone Deacetylase Inhibitor SAHA in Cutaneous T-Cell Lymphoma Cells: Relevance to Mechanism of Therapeutic Action. <i>Journal of Investigative Dermatology</i> , 2005, 125, 1045-1052.	0.3	219
249	Primary cutaneous B-cell lymphoma. <i>Journal of the American Academy of Dermatology</i> , 2005, 53, 478-483.	0.6	65
250	Degree of CD25 Expression in T-Cell Lymphoma Is Dependent on Tissue Site. <i>Clinical Cancer Research</i> , 2004, 10, 5587-5594.	3.2	34
251	Up-regulation of Flotillin-2 Is Associated with Melanoma Progression and Modulates Expression of the Thrombin Receptor Protease Activated Receptor 1. <i>Cancer Research</i> , 2004, 64, 7361-7369.	0.4	92
252	Bone Marrow Transplantation in Jehovah's Witnesses. <i>Leukemia and Lymphoma</i> , 2004, 45, 635-636.	0.6	3

#	ARTICLE	IF	CITATIONS
253	The Novel Synthetic Oleanane Triterpenoid CDDO (2-cyano-3, 12-dioxoolean-1, 9-dien-28-oic acid) Induces Apoptosis in Mycosis Fungoides/Sézary Syndrome Cells. <i>Journal of Investigative Dermatology</i> , 2004, 123, 380-387.	0.3	27
254	Phase II study of pentostatin in advanced T-cell lymphoid malignancies. <i>Cancer</i> , 2004, 100, 342-349.	2.0	75
255	Lymphomatoid Papulosis from Childhood with Anaplastic Large-Cell Lymphoma of the Small Bowel. <i>Clinical Lymphoma and Myeloma</i> , 2004, 5, 190-193.	2.1	13
256	Pilot study of etanercept in patients with relapsed cutaneous T-cell lymphomas. <i>Journal of the American Academy of Dermatology</i> , 2004, 51, 200-204.	0.6	29
257	Tazarotene 0.1% gel for refractory mycosis fungoides lesions: an open-label pilot study. <i>Journal of the American Academy of Dermatology</i> , 2004, 50, 600-607.	0.6	57
258	Cutaneous T-cell lymphoma. <i>Journal of the American Academy of Dermatology</i> , 2004, 51, 43-45.	0.6	20
259	A systematic approach to diagnosis of mature T-cell leukemias reveals heterogeneity among WHO categories. <i>Blood</i> , 2004, 104, 328-335.	0.6	182
260	Phase I multi-center study of intravenous Bcx-1777 in patients with refractory cutaneous T-cell lymphoma. <i>Journal of Clinical Oncology</i> , 2004, 22, 6733-6733.	0.8	0
261	Phase I multi-center study of intravenous Bcx-1777 in patients with refractory cutaneous T-cell lymphoma. <i>Journal of Clinical Oncology</i> , 2004, 22, 6733-6733.	0.8	0
262	Extracorporeal Photopheresis for the Treatment of Cutaneous T-Cell Lymphoma. <i>Journal of Cutaneous Medicine and Surgery</i> , 2003, 7, 3-7.	0.6	29
263	Mycosis fungoides associated with malignant melanoma and dysplastic nevus syndrome. <i>International Journal of Dermatology</i> , 2003, 42, 116-122.	0.5	35
264	Long-term control of mycosis fungoides of the hands with topical bexarotene. <i>International Journal of Dermatology</i> , 2003, 42, 238-241.	0.5	9
265	Tazarotene-Induced Gene 3 Is Suppressed in Basal Cell Carcinomas and Reversed In Vivo by Tazarotene Application. <i>Journal of Investigative Dermatology</i> , 2003, 121, 902-909.	0.3	37
266	Alopecia Areata Registry: An Overview. <i>Journal of Investigative Dermatology Symposium Proceedings</i> , 2003, 8, 219-221.	0.8	23
267	Retinoids: therapeutic applications and mechanisms of action in cutaneous T-cell lymphoma. <i>Dermatologic Therapy</i> , 2003, 16, 322-330.	0.8	67
268	Topical and systemic retinoid therapy for cutaneous T-cell lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2003, 17, 1405-1419.	0.9	36
269	Analysis of long-term outcomes of combined modality therapy for cutaneous T-cell lymphoma. <i>Journal of the American Academy of Dermatology</i> , 2003, 49, 35-49.	0.6	68
270	Mycosis Fungoides with Follicular Mucinosis Displaying Aggressive Tumor-Stage Transformation. <i>American Journal of Clinical Dermatology</i> , 2003, 4, 429-433.	3.3	16

#	ARTICLE	IF	CITATIONS
271	Extracorporeal Photopheresis for the Treatment of Cutaneous T-Cell Lymphoma. Journal of Cutaneous Medicine and Surgery, 2003, 7, 3-7.	0.6	40
272	Cytomegalovirus seropositivity is significantly associated with mycosis fungoides and Sezary syndrome. Blood, 2003, 101, 2132-2135.	0.6	89
273	Treatment of Refractory Peripheral T-cell Lymphoma with Denileukin Diftitox (ONTAK [®]). Leukemia and Lymphoma, 2002, 43, 121-126.	0.6	60
274	Phase 1 and 2 Trial of Bexarotene Gel for Skin-Directed Treatment of Patients With Cutaneous T-Cell Lymphoma. Archives of Dermatology, 2002, 138, 325-32.	1.7	178
275	Clonal heterogeneity in mycosis fungoides and its relationship to clinical course. Blood, 2002, 100, 3369-3373.	0.6	133
276	Quality-of-Life Improvements in Cutaneous T-Cell Lymphoma Patients Treated with Denileukin Diftitox (ONTAK [®]). Clinical Lymphoma and Myeloma, 2002, 2, 222-228.	2.1	95
277	Treatment of Cutaneous T Cell Lymphoma. American Journal of Clinical Dermatology, 2002, 3, 193-215.	3.3	72
278	Update on erythrodermic cutaneous T-cell lymphoma: Report of the international society for cutaneous lymphomas. Journal of the American Academy of Dermatology, 2002, 46, 95-106.	0.6	448
279	Cold urticaria in a patient with mycosis fungoides. Journal of the American Academy of Dermatology, 2002, 47, 608-610.	0.6	5
280	Optimizing bexarotene therapy for cutaneous T-cell lymphoma. Journal of the American Academy of Dermatology, 2002, 47, 672-684.	0.6	185
281	Increased serum immunoglobulin levels are common in mycosis fungoides and Sezary syndrome. Journal of the American Academy of Dermatology, 2002, 47, 685-691.	0.6	15
282	UVA1 dose and cell cycle conditions influence the outcome of UVB-induced HIV activation. Photodermatology Photoimmunology and Photomedicine, 2002, 18, 104-104.	0.7	0
283	A stable aberrant immunophenotype characterizes nearly all cases of cutaneous T-cell lymphoma in blood and can be used to monitor response to therapy. BMC Clinical Pathology, 2002, 2, 5.	1.8	58
284	The genetics of alopecia areata. Clinics in Dermatology, 2001, 19, 135-139.	0.8	26
285	CUTANEOUS T-CELL LYMPHOMA. Dermatologic Clinics, 2001, 19, 737-748.	1.0	12
286	Therapy options in cutaneous T-cell lymphoma. Expert Review of Anticancer Therapy, 2001, 1, 403-420.	1.1	13
287	Bexarotene Is Effective and Safe for Treatment of Refractory Advanced-Stage Cutaneous T-Cell Lymphoma: Multinational Phase II-III Trial Results. Journal of Clinical Oncology, 2001, 19, 2456-2471.	0.8	682
288	Pivotal Phase III Trial of Two Dose Levels of Denileukin Diftitox for the Treatment of Cutaneous T-Cell Lymphoma. Journal of Clinical Oncology, 2001, 19, 376-388.	0.8	615

#	ARTICLE	IF	CITATIONS
289	Persistent Atypical Lymphocytic Hyperplasia Following Tick Bite in a Child: Report of a Case and Review of the Literature. <i>Pediatric Dermatology</i> , 2001, 18, 481-484.	0.5	29
290	Transient CD30+ nodal transformation of cutaneous T-cell lymphoma associated with cyclosporine treatment. <i>International Journal of Dermatology</i> , 2001, 40, 505-511.	0.5	27
291	The T-Cell Chemokine Receptor CXCR3 Is Expressed Highly in Low-Grade Mycosis Fungoides. <i>American Journal of Clinical Pathology</i> , 2001, 115, 413-421.	0.4	80
292	Absence of CD26 Expression Is a Useful Marker for Diagnosis of T-Cell Lymphoma in Peripheral Blood. <i>American Journal of Clinical Pathology</i> , 2001, 115, 885-892.	0.4	179
293	The Role for Interleukin-12 Therapy of Cutaneous T Cell Lymphoma. <i>Annals of the New York Academy of Sciences</i> , 2001, 941, 177-184.	1.8	49
294	Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. <i>Archives of Dermatology</i> , 2001, 137, 581-93.	1.7	280
295	Fas ligand expression by neoplastic T lymphocytes mediates elimination of CD8+ cytotoxic T lymphocytes in mycosis fungoides: a potential mechanism of tumor immune escape?. <i>Clinical Cancer Research</i> , 2001, 7, 2682-92.	3.2	47
296	Topical Treatment of Cutaneous Lesions of Acquired Immunodeficiency Syndrome-Related Kaposi Sarcoma Using Alitretinoin Gel. <i>Archives of Dermatology</i> , 2000, 136, 1461-9.	1.7	68
297	Cytokine expression patterns distinguish HIV associated skin diseases. <i>Experimental Dermatology</i> , 2000, 9, 341-350.	1.4	18
298	Alitretinoin. <i>American Journal of Clinical Dermatology</i> , 2000, 1, 315-316.	3.3	0
299	EMERGING NEW THERAPIES FOR CUTANEOUS T-CELL LYMPHOMA. <i>Dermatologic Clinics</i> , 2000, 18, 147-156.	1.0	58
300	Enterococcal Eschars in Cutaneous T-Cell Lymphoma Tumors: A Distinct Clinical Entity. <i>Clinical Lymphoma and Myeloma</i> , 2000, 1, 141-145.	2.1	11
301	Treatment of Cutaneous T-Cell Lymphoma from a Dermatologist's Perspective. <i>Clinical Lymphoma and Myeloma</i> , 2000, 1, S15-S20.	2.1	6
302	Bexarotene and DAB389IL-2 (Denileukin Diftitox, ONTAK) in Treatment of Cutaneous T-Cell Lymphomas: Algorithms. <i>Clinical Lymphoma and Myeloma</i> , 2000, 1, S51-S55.	2.1	25
303	Expression of a retinoid-inducible tumor suppressor, Tazarotene-inducible gene-3, is decreased in psoriasis and skin cancer. <i>Clinical Cancer Research</i> , 2000, 6, 3249-59.	3.2	57
304	Pentostatin Therapy of T-Cell Lymphomas With Cutaneous Manifestations. <i>Journal of Clinical Oncology</i> , 1999, 17, 3117-3121.	0.8	102
305	Alopecia Areata in Families: Association with the HLA Locus. <i>Journal of Investigative Dermatology Symposium Proceedings</i> , 1999, 4, 220-223.	0.8	80
306	Central Hypothyroidism Associated with Retinoid X Receptor-Selective Ligands. <i>New England Journal of Medicine</i> , 1999, 340, 1075-1079.	13.9	286

#	ARTICLE	IF	CITATIONS
307	Flotillin 2 is distinct from epidermal surface antigen (ESA) and is associated with filopodia formation. , 1999, 75, 147-159.		33
308	Prognostic factor analysis in mycosis fungoides/S�azary syndrome. Journal of the American Academy of Dermatology, 1999, 40, 914-924.	0.6	160
309	Effectiveness of Photopheresis in Sezary Syndrome. Archives of Dermatology, 1999, 135, 995-a-997.	1.7	27
310	Dysregulated Synthesis of Intracellular Type 1 and Type 2 Cytokines by T Cells of Patients with Cutaneous T-Cell Lymphoma. Vaccine Journal, 1999, 6, 79-84.	2.6	57
311	DAB389IL2 diphtheria fusion toxin produces clinical responses in tumor stage cutaneous T cell lymphoma. , 1998, 58, 87-90.		59
312	Nerve growth factor in normal and psoriatic skin equivalent models. Archives of Dermatological Research, 1998, 290, 610-614.	1.1	4
313	The pathogenesis of psoriasis and the mechanism of action of tazarotene. Journal of the American Academy of Dermatology, 1998, 39, S129-S133.	0.6	49
314	Alopecia areata and cytomegalovirus infection in twins: Genes versus environment?. Journal of the American Academy of Dermatology, 1998, 38, 418-425.	0.6	118
315	Tumor Necrosis Factor-� and Interferon-�, but not HTLV-I Tax, are Likely Factors in the Epidermotropism of Cutaneous T-Cell Lymphoma via Induction of Interferon-Inducible Protein-10. Leukemia and Lymphoma, 1998, 29, 315-328.	0.6	25
316	Transformation of Mycosis Fungoides/Sezary Syndrome: Clinical Characteristics and Prognosis. Blood, 1998, 92, 1150-1159.	0.6	285
317	Identification and characterization of a retinoid-induced class II tumor suppressor/growth regulatory gene. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 14811-14815.	3.3	147
318	Transformation of mycosis fungoides/Sezary syndrome: clinical characteristics and prognosis. Blood, 1998, 92, 1150-9.	0.6	46
319	Tazarotene: a review of its pharmacological profile and potential for clinical use in psoriasis. Expert Opinion on Investigational Drugs, 1997, 6, 1537-1551.	1.9	17
320	Tazarotene gel, a new retinoid, for topical therapy of psoriasis: Vehicle-controlled study of safety, efficacy, and duration of therapeutic effect. Journal of the American Academy of Dermatology, 1997, 37, 85-92.	0.6	166
321	Follicular mucinosis associated with scarring alopecia, oligoclonal T-cell receptor V� expansion, and Staphylococcus aureus: When does follicular mucinosis become mycosis fungoides?. Journal of the American Academy of Dermatology, 1997, 37, 828-831.	0.6	52
322	Molecular mechanisms of tazarotene action in psoriasis. Journal of the American Academy of Dermatology, 1997, 37, S18-S24.	0.6	96
323	Association of Erythrodermic Cutaneous T-Cell Lymphoma, Superantigen-Positive Staphylococcus aureus, and Oligoclonal T-Cell Receptor V� Gene Expansion. Blood, 1997, 89, 32-40.	0.6	217
324	Tazarotene-induced Gene 2 (TIG2), a Novel Retinoid-Responsive Gene in Skin. Journal of Investigative Dermatology, 1997, 109, 91-95.	0.3	244

#	ARTICLE	IF	CITATIONS
325	The sign of Leser-Trélat. <i>Medical and Pediatric Oncology</i> , 1997, 28, 234-237.	1.0	6
326	Association of erythrodermic cutaneous T-cell lymphoma, superantigen-positive <i>Staphylococcus aureus</i> , and oligoclonal T-cell receptor V beta gene expansion. <i>Blood</i> , 1997, 89, 32-40.	0.6	81
327	Interferon-inducible protein 10 as a possible factor in the pathogenesis of cutaneous T-cell lymphomas. <i>Clinical Cancer Research</i> , 1997, 3, 169-77.	3.2	16
328	Combined modality therapy for cutaneous T-cell lymphoma. <i>Journal of the American Academy of Dermatology</i> , 1996, 34, 1022-1029.	0.6	95
329	Photopheresis therapy for cutaneous T-cell lymphoma. <i>Journal of the American Academy of Dermatology</i> , 1996, 35, 573-579.	0.6	135
330	Effects of fibroblast-keratinocyte interactions on the secretion of interleukin-8. <i>Bulletin of Experimental Biology and Medicine</i> , 1996, 121, 167-170.	0.3	2
331	Tazarotene-Induced Gene 1 (TIG1), a Novel Retinoic Acid Receptor-Responsive Gene in Skin. <i>Journal of Investigative Dermatology</i> , 1996, 106, 269-274.	0.3	113
332	HLA-DR5 and DQB1*03 Class II Alleles Are Associated With Cutaneous T-Cell Lymphoma. <i>Journal of Investigative Dermatology</i> , 1996, 107, 373-376.	0.3	91
333	Interferon-Inducible Protein-10 and the Pathogenesis of Cutaneous T-Cell Lymphomas. <i>Leukemia and Lymphoma</i> , 1996, 24, 103-110.	0.6	12
334	Amplification of genomic DNA demonstrates the presence of the t(2;5) (p23;q35) in anaplastic large cell lymphoma, but not in other non-Hodgkin's lymphomas, Hodgkin's disease, or lymphomatoid papulosis. <i>Blood</i> , 1996, 88, 1771-1779.	0.6	71
335	Amplification of genomic DNA demonstrates the presence of the t(2;5) (p23;q35) in anaplastic large cell lymphoma, but not in other non-Hodgkin's lymphomas, Hodgkin's disease, or lymphomatoid papulosis. <i>Blood</i> , 1996, 88, 1771-1779.	0.6	2
336	Amplification of genomic DNA demonstrates the presence of the t(2;5) (p23;q35) in anaplastic large cell lymphoma, but not in other non-Hodgkin's lymphomas, Hodgkin's disease, or lymphomatoid papulosis. <i>Blood</i> , 1996, 88, 1771-9.	0.6	13
337	Cytokine loops involving interferon-gamma and IP-10, a cytokine chemotactic for CD4+ lymphocytes: an explanation for the epidermotropism of cutaneous T-cell lymphoma? [see comments]. <i>Blood</i> , 1995, 86, 651-658.	0.6	79
338	Analysis of HLA-D Locus Alleles in Alopecia Areata Patients and Families. <i>Journal of Investigative Dermatology</i> , 1995, 104, 5-6.	0.3	41
339	Epidermal Surface Antigen (M517S1) Is Highly Conserved between Mouse and Human. <i>Genomics</i> , 1995, 27, 251-258.	1.3	16
340	Werner's syndrome. <i>Dermatologic Clinics</i> , 1995, 13, 163-8.	1.0	7
341	2-Chlorodeoxyadenosine therapy in patients with T-cell lymphoproliferative disorders. <i>Blood</i> , 1994, 84, 733-738.	0.6	61
342	Keratinocyte Transglutaminase Expression Varies in Squamous Cell Carcinomas. <i>Journal of Investigative Dermatology</i> , 1994, 102, 462-469.	0.3	25

#	ARTICLE	IF	CITATIONS
343	In vivo fluorescence spectroscopy and imaging of human skin tumours. <i>Lasers in Medical Science</i> , 1994, 9, 191-201.	1.0	109
344	Human Leukocyte Antigen-DQB1*03 Alleles Are Associated with Alopecia Areata. <i>Journal of Investigative Dermatology</i> , 1994, 103, 758-763.	0.3	99
345	High-frequency sonography of the skin. <i>Journal of the European Academy of Dermatology and Venereology</i> , 1994, 3, 47-55.	1.3	4
346	Response of psoriasis to a new topical retinoid, AGN 190168. <i>Journal of the American Academy of Dermatology</i> , 1994, 30, 581-590.	0.6	121
347	Emergence of leprosy in a patient with mycosis fungoides. <i>Journal of the American Academy of Dermatology</i> , 1994, 30, 313-315.	0.6	16
348	Cloning and characterization of a novel epidermal cell surface antigen (ESA).. <i>Journal of Biological Chemistry</i> , 1994, 269, 19983-19991.	1.6	36
349	2-Chlorodeoxyadenosine therapy in patients with T-cell lymphoproliferative disorders. <i>Blood</i> , 1994, 84, 733-738.	0.6	2
350	2-Chlorodeoxyadenosine therapy in patients with T-cell lymphoproliferative disorders. <i>Blood</i> , 1994, 84, 733-8.	0.6	10
351	Cloning and characterization of a novel epidermal cell surface antigen (ESA). <i>Journal of Biological Chemistry</i> , 1994, 269, 19983-91.	1.6	29
352	The gene for a novel epidermal antigen maps near the neurofibromatosis 1 gene. <i>Genomics</i> , 1992, 14, 369-376.	1.3	9
353	Blue Rubber Bleb Nevus Syndrome: Laser Photocoagulation of Colonic Hemangiomas in a Child with Microcytic Anemia. <i>Pediatric Dermatology</i> , 1992, 9, 91-94.	0.5	29
354	The human gene for an epidermal surface antigen (M17S1) is located at 17q11â€“12. <i>Genomics</i> , 1991, 11, 481-482.	1.3	8
355	HLA-D Locus Associations in Alopecia Areata. <i>Archives of Dermatology</i> , 1991, 127, 64.	1.7	44
356	Human immunodeficiency virus-associated psoriasis, psoriatic arthritis, and Reiter's syndrome: A disease continuum?. <i>Arthritis and Rheumatism</i> , 1990, 33, 1574-1578.	6.7	106
357	Expression of Pemphigus Vulgaris Antigen in Cultured Human Keratinocytes: Effect of Inhibitors, Tunicamycin, and Lectins. <i>Journal of Investigative Dermatology</i> , 1988, 90, 708-715.	0.3	11
358	Use of monospecific antisera and cRNA probes to localize the major changes in keratin expression during normal and abnormal epidermal differentiation.. <i>Journal of Cell Biology</i> , 1988, 107, 427-446.	2.3	345